JP6882339B2 - ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 - Google Patents

ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 Download PDF

Info

Publication number
JP6882339B2
JP6882339B2 JP2018559273A JP2018559273A JP6882339B2 JP 6882339 B2 JP6882339 B2 JP 6882339B2 JP 2018559273 A JP2018559273 A JP 2018559273A JP 2018559273 A JP2018559273 A JP 2018559273A JP 6882339 B2 JP6882339 B2 JP 6882339B2
Authority
JP
Japan
Prior art keywords
cell
peracetylgalactose
protein
culture
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018559273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514411A5 (https=
JP2019514411A (ja
Inventor
ヨルダン マルティン
ヨルダン マルティン
ルクレール ガブリエル
ルクレール ガブリエル
スケ ジョナタン
スケ ジョナタン
ブロリー エルベ
ブロリー エルベ
ブリュールマン ダービト
ブリュールマン ダービト
Original Assignee
アレス トレーディング ソシエテ アノニム
アレス トレーディング ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレス トレーディング ソシエテ アノニム, アレス トレーディング ソシエテ アノニム filed Critical アレス トレーディング ソシエテ アノニム
Publication of JP2019514411A publication Critical patent/JP2019514411A/ja
Publication of JP2019514411A5 publication Critical patent/JP2019514411A5/ja
Application granted granted Critical
Publication of JP6882339B2 publication Critical patent/JP6882339B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018559273A 2016-05-10 2017-05-10 ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法 Expired - Fee Related JP6882339B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16169062.3 2016-05-10
EP16169062 2016-05-10
PCT/EP2017/061181 WO2017194605A1 (en) 2016-05-10 2017-05-10 Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose

Publications (3)

Publication Number Publication Date
JP2019514411A JP2019514411A (ja) 2019-06-06
JP2019514411A5 JP2019514411A5 (https=) 2020-06-18
JP6882339B2 true JP6882339B2 (ja) 2021-06-02

Family

ID=56026651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018559273A Expired - Fee Related JP6882339B2 (ja) 2016-05-10 2017-05-10 ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法

Country Status (9)

Country Link
US (1) US11118208B2 (https=)
EP (1) EP3455363B1 (https=)
JP (1) JP6882339B2 (https=)
CN (1) CN109072273B (https=)
AU (2) AU2017264541A1 (https=)
CA (1) CA3022769A1 (https=)
ES (1) ES2908067T3 (https=)
IL (1) IL262875B (https=)
WO (1) WO2017194605A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3397282A4 (en) 2015-12-30 2019-08-07 Momenta Pharmaceuticals, Inc. METHODS RELATING TO BIOLOGICA
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
AU2019336148B2 (en) 2018-09-06 2025-08-14 Momenta Pharmaceuticals, Inc. Methods of continuous cell culture
WO2020142275A1 (en) * 2018-12-31 2020-07-09 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
CN113549667A (zh) * 2021-07-21 2021-10-26 杭州奕安济世生物药业有限公司 一种降低抗体半乳糖基化的方法
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
CN121058875A (zh) * 2025-10-11 2025-12-05 广东海洋大学 一种负载脂溶性多酚的碱诱导糖基化罗非鱼蛋白水解物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163551B2 (en) * 2008-05-02 2012-04-24 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
DK2608796T3 (en) * 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
WO2015115849A1 (ko) * 2014-01-29 2015-08-06 주식회사 엘지생명과학 배양배지의 최적화를 통한 재조합 단백질의 갈락토오스화를 조절하는 방법
US20160039924A1 (en) * 2014-08-05 2016-02-11 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen

Also Published As

Publication number Publication date
ES2908067T3 (es) 2022-04-27
JP2019514411A (ja) 2019-06-06
US20190153497A1 (en) 2019-05-23
IL262875B (en) 2022-05-01
CA3022769A1 (en) 2017-11-16
EP3455363A1 (en) 2019-03-20
AU2021258023A1 (en) 2021-11-25
AU2021258023B2 (en) 2023-11-16
US11118208B2 (en) 2021-09-14
WO2017194605A1 (en) 2017-11-16
EP3455363B1 (en) 2021-12-08
CN109072273A (zh) 2018-12-21
CN109072273B (zh) 2022-04-15
IL262875A (en) 2018-12-31
AU2017264541A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP6882339B2 (ja) ペルアセチルガラクトースを使った組換えタンパク質のタンパク質ガラクトシル化プロファイルを改変する方法
JP6971221B2 (ja) 組換えタンパク質のガラクトース含有量を増加させる方法
JP7267284B2 (ja) ポリエーテルイオノフォアを使用するタンパク質マンノシル化プロファイルの調節方法
TWI832345B (zh) 用於增加重組蛋白質之甘露糖含量之方法
KR102894782B1 (ko) 세포 배양에서 생산된 재조합 당단백질의 글리코실화 프로파일의 변형 방법
AU2016354052B2 (en) Methods for modulating production profiles of recombinant proteins
KR20230109674A (ko) Fab 고 만노스 당형
CN115537445A (zh) 用含尿苷和n-乙酰葡糖胺的培养基调节甘露聚糖糖型
JP2019526265A (ja) 組換えタンパク質の生産プロファイルを改変するための方法
HK40089653A (zh) Fab高甘露糖糖型
WO2016162514A1 (en) Methods for modulating protein glycosylation profiles of recombinant proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200501

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210506

R150 Certificate of patent or registration of utility model

Ref document number: 6882339

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees